A reliable PTMRS may offer clinicians an efficient tool for risk stratification and outcome prediction, while the identification of hub genes such as PDGFRB points toward new directions for targeted therapy development in advanced CRC. The gene discussed is PDGFRB; the disease is colorectal carcinoma.